NCT06454682View on ClinicalTrials.gov

An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

June 21, 2025

Study Completion Date

August 2, 2031

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

RJK002 Intrathecal injection

Eligible subjects will receive a single intrathecal administration of investigational product with dose 3E13 vg/person, 6E13 vg/person, and 1.2E14 vg/person sequentially.

Trial Locations (1)

Unknown

The First Affiliated Hospital Fujian Medical University, Fuzhou

All Listed Sponsors

lead

RJK Biopharma Ltd

INDUSTRY